Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Archimedes Pharma cancer pain drug shows promise in study

Archimedes Pharma cancer pain drug shows promise in study

18th October 2010

Archimedes Pharma has highlighted recently-published data that highlights the potential benefits of one of its new treatments for breakthrough cancer pain.

Medical journal Pain has published the results from a pivotal clinical trial of Archimedes' fentanyl pectin nasal spray (FPNS), which assessed the treatment's performance among patients who have proven unresponsive to background opioid therapy.

The drug was able to meet its primary efficacy endpoint of delivering significant reductions in pain intensity 30 minutes after dosing when compared to placebo, with many of these benefits taking effect after only five minutes.

Jeff Buchalter, president and chief executive officer of Archimedes Pharma, said this represents an important development in treating a condition which is currently "inadequately managed".

He added: "FPNS' proprietary pectin-based transmucosal delivery system is characterised by reduced time to onset of effect, which helps overcome one limitation associated with treatment by conventional opioids."

Last month, the firm was granted European regulatory approval for the drug, which is being marketed under the name PecFent.ADNFCR-8000103-ID-800120751-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.